Women age 75 years and older should continue to get screening mammograms because of the comparatively high incidence of breast cancer found in this age group, according to a new study.
In a study published in the journal NPJ Breast Cancer, researchers reported they used a form of artificial intelligence called machine learning, or deep learning, to train a computer to identify certain features of breast cancer tumors from images.
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in an animal model of the disease.
New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalised medicine ever nearer.
Phone calls are more effective reminders for patients to book cancer screening appointments than mailed letters but are also more costly, suggests a new study from St. Michael's Hospital.
Uncovering a novel mechanism that promotes growth of breast cancer bone metastasis has revealed a potential Achilles' heel for these cancer cells.
EPFL scientists have uncovered that next to estrogen receptor positive and negative there are cells with very low amounts of the receptor protein. The discovery has significant implications for the role of the receptor in the growth and development of the breast and breast cancer development.
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
Three USC Viterbi School of Engineering researchers -- Assistant Professor Stacey Finley, Professor Pin Wang and Assistant Professor Nick Graham -- have just published a paper in 'Biophysical Journal' that sheds light on Chimeric Antigen Receptor (CAR) T cell therapy, information that could one day result in better cancer therapies with fewer side effects.
Researchers from Karolinska Institutet in Sweden have identified a protein that determines the identity and invasive properties of breast cancer cells. The finding could lead to the development of new therapeutic and diagnostic strategies to target breast cancer invasion and metastasis. The study is published in the scientific journal Cancer Research.